Risk factors for progression to pneumonia
| Characteristic . | Patients with PIV pneumonia (n = 95), N (%) . | Patients with PIV URI (n = 105), N (%) . | Univariate analysis (P) . |
|---|---|---|---|
| Age ≥ 65 y | 19 (20) | 11 (10) | .06 |
| Relapse or refractory stage of underlying malignancy | 34/95 (36) | 26/104 (25) | .1 |
| Underlying condition | .002 | ||
| HSCT | 46 (48) | 74 (70) | |
| Leukemia | 49 (52) | 31 (30) | |
| GVHD | 22/46 (48) | 26/74 (35) | .17 |
| Type of PIV | |||
| Type I | 9 (9) | 13 (12) | .89 |
| Type II | 3 (3) | 3 (3) | |
| Type III | 83 (87) | 89 (85) | |
| Neutropenia (ANC < 500 μ/L) within a week of diagnosis to resolution of symptoms | 53/94 (56) | 22/102 (22) | < .0001 |
| Lymphopenia (ALC < 200 μ/L) within a week of diagnosis to resolution of symptoms | 62/94 (66) | 43/102 (42) | .001 |
| APACHE II score at diagnosis of PIV infection, median (range) | 13 (5-30) | 9 (3-20) | < .0001 |
| Steroid use | |||
| Corticosteroids | 52 (55) | 70 (67) | .08 |
| Prednisolone ≥ 600 mg | 35 (37) | 45 (43) | .39 |
| Chemotherapy within a month of diagnosis of PIV infection | 68 (72) | 44 (42) | < .0001 |
| Respiratory coinfections within a month of diagnosis of PIV infection | 41 (43) | 15 (14) | < .0001 |
| Therapy at URI stage | |||
| Aerosolized ribavirin and/or IVIG alone | 15/36 (42) | 22/105 (21) | .015 |
| Aerosolized ribavirin with or without IVIG | 9/36 (25) | 2/105 (2) | < .0001 |
| Characteristic . | Patients with PIV pneumonia (n = 95), N (%) . | Patients with PIV URI (n = 105), N (%) . | Univariate analysis (P) . |
|---|---|---|---|
| Age ≥ 65 y | 19 (20) | 11 (10) | .06 |
| Relapse or refractory stage of underlying malignancy | 34/95 (36) | 26/104 (25) | .1 |
| Underlying condition | .002 | ||
| HSCT | 46 (48) | 74 (70) | |
| Leukemia | 49 (52) | 31 (30) | |
| GVHD | 22/46 (48) | 26/74 (35) | .17 |
| Type of PIV | |||
| Type I | 9 (9) | 13 (12) | .89 |
| Type II | 3 (3) | 3 (3) | |
| Type III | 83 (87) | 89 (85) | |
| Neutropenia (ANC < 500 μ/L) within a week of diagnosis to resolution of symptoms | 53/94 (56) | 22/102 (22) | < .0001 |
| Lymphopenia (ALC < 200 μ/L) within a week of diagnosis to resolution of symptoms | 62/94 (66) | 43/102 (42) | .001 |
| APACHE II score at diagnosis of PIV infection, median (range) | 13 (5-30) | 9 (3-20) | < .0001 |
| Steroid use | |||
| Corticosteroids | 52 (55) | 70 (67) | .08 |
| Prednisolone ≥ 600 mg | 35 (37) | 45 (43) | .39 |
| Chemotherapy within a month of diagnosis of PIV infection | 68 (72) | 44 (42) | < .0001 |
| Respiratory coinfections within a month of diagnosis of PIV infection | 41 (43) | 15 (14) | < .0001 |
| Therapy at URI stage | |||
| Aerosolized ribavirin and/or IVIG alone | 15/36 (42) | 22/105 (21) | .015 |
| Aerosolized ribavirin with or without IVIG | 9/36 (25) | 2/105 (2) | < .0001 |